MET and hepatocellular carcinoma: demonstrated a potential association between MET expression and HCC patient responses to sorafenib therapy, revealing that HCC patients with elevated phosphorylated MET (p-MET) levels exhibited resistance to adjuvant sorafenib treatment, suggesting that MET activation in HCC may serve as a promising predictive biomarker for therapeutic response (97).